CASPR2自己抗体がヒト脳オルガノイドにおける神経興奮亢進を誘発する
Ana Rafaela Oliveira1,2,3, Giuseppe Cammarata1,4, Catarina Seabra1,3
1CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Journal of neurochemistry
|February 23, 2026
まとめ
母体の抗接合因子関連タンパク質様2(CASPR2)を標的とする自己抗体は、胎児の脳発達を妨げる可能性があります。ヒト神経オルガノイドにおける抗CASPR2抗体への曝露は、神経発達障害の特徴である神経興奮亢進を誘発しました。
科学分野:
- 神経科学
- 発生生物学
- 免疫学
背景:
- 妊娠中の脳反応性抗体の胎盤通過は、神経発達障害のリスクとなります。
- 接合因子関連タンパク質様2(CASPR2)は、胎児の神経発達に関与する母体自己抗体の標的です。
- CASPR2抗体がヒト脳発達に及ぼす正確な影響は、よく理解されていません。
研究 の 目的:
- CASPR2自己抗体がヒト脳発達に及ぼす神経生理学的影響を調査すること。
- CASPR2抗体誘発性神経発達異常のメカニズムを解明すること。
主な方法:
- 抗CASPR2抗体を含む培地で、未誘導のヒト神経オルガノイドを6ヶ月間培養しました。
- 急性オルガノイドスライスで、ホールセルパッチクランプおよびカルシウムイメージングを使用して神経生理学的特性評価を行いました。
主要な成果:
- CASPR2抗体の曝露は、自発的シナプス活動を有意に増加させました。
- 活動電位発火の最大頻度と自発的ネットワーク活動の増強が観察されました。
- 活動電位波形の変化は、電圧依存性カリウムチャネルの調節におけるCASPR2の役割を示唆しています。
結論:
- CASPR2自己抗体は、ヒト神経オルガノイドにおいて神経興奮亢進を誘発します。
- この神経興奮亢進フェノタイプは、神経発達障害モデルで見られる所見を反映しています。
- CASPR2自己抗体は、発達中の神経興奮亢進を駆動する上で病理学的役割を果たす可能性があります。
関連する概念動画
GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Postsynaptic Potential (PSP)
Postsynaptic potential (PSP) refers to a change in the electrical potential of a neuron when neurotransmitters released by presynaptic neurons bind to postsynaptic receptors. This potential can either be excitatory, leading to depolarization and ultimately action potential generation, or inhibitory, leading to hyperpolarization and suppression of the postsynaptic neuron.
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


